|Podcasts|July 31, 2019

Perusing Breakthroughs in Breast Cancer in Pasadena

We traveled to Pasadena, California, for a State of the Science Summit™ on Breast Cancer, which featured insights from the faculty from City of Hope.

We recently traveled to Pasadena, California, for a State of the Science Summit™ on Breast Cancer. The meeting, which featured insight from experts from City of Hope, covered a wide array of topics, ranging from advances made in HER2-positive breast cancer, to key trials in metastatic triple-negative disease, to genomic assays used in hormone receptor—positive disease, to axilla management.

Stay up to date on the most recent and practice-changing oncology data

Latest CME

In-Person + Virtual Event

10th Annual Live Medical Crossfire®: Hematologic Malignancies

July 11-12, 2026

Perusing Breakthroughs in Breast Cancer in Pasadena

Related Content

FDA Flashback: Breast Cancer Decisions and News From May 2026

ASCO 2026 Plenary: RASolute 302

Five Under 5: Top Oncology Videos for the Week of 6/1/2026

The OncFive: Top Oncology Articles for the Week of 5/31

Tumor Board: Clinical Integration of Molecular Profiling in Glioma—Transforming the Use of Targeted Therapy

Latest CME

10th Annual Live Medical Crossfire®: Hematologic Malignancies

Community Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | Nevada Oncology Society

Community Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | The Arizona Clinical Oncology Society

Community Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | Missouri Oncology Society

Wyoming State Oncology Society

Kansas Society of Clinical Oncology

North Carolina Oncology Association

Live Tumor Board: Exploring Novel Targets and Breakthrough Treatment Strategies in Extrapulmonary Neuroendocrine Carcinomas

A Case-Guided Discussion on Managing Immune Thrombocytopenic Purpura (ITP)

ADCs and Bispecific Antibodies Across Solid Tumors: Integrating New Targets, New Data, and New Decisions

Medical Crossfire®: Precision Oncology in NSCLC – Translating HER2 and TROP2 Innovation into Practice-Changing Care

Community Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | Wisconsin Association of Hematology and Oncology

Louisiana Oncology Society

Missouri Oncology Society

New Mexico Society of Clinical Oncology

Cases & Conversations™: Transforming AML Care—Precision Strategies, Evolving Therapies, and Clinical Insights

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Cases and Conversations™: Sorting Through the Expanding Treatment Options for Patients with Relapsed/Refractory Multiple Myeloma

Medical Crossfire®: Precision Medicine in Glioma Treatment — Integration of Molecular Profiling to Inform Targeted Therapies

Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing

Medical Crossfire®: Improving Patient Outcomes in Myeloproliferative Neoplasms With Novel Therapeutic Approaches

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

GI Tumor Board—Applying Recent Advances in Biomarker Testing and Treatment in Metastatic Colorectal Cancer

Medical Crossfire®: Harnessing the Power of Modern Therapies in Newly Diagnosed Multiple Myeloma

PER Tumor Board®: Applying Recent Advances to Transform the Treatment Paradigm in SCLC—Expert Perspectives on New Approvals and Emerging Strategies

Medical Crossfire®: Integrating Next-Generation Endocrine Targeting Therapies to Improve Outcomes for Patients With HR+/HER2- Breast Cancer

Wisconsin Association of Hematology and Oncology

Indiana Oncology Society

Arkansas Association of Cancer Professionals

Rhode Island Oncology Society

Kentucky Society of Clinical Oncology

Breast Cancer Tumor Board: Targeting TROP2 – Innovations in Triple-Negative Breast Cancer Treatment

Empire State Hematology & Oncology Society (New York)

Minnesota Society of Clinical Oncology

South Carolina Oncology Society

West Virginia Oncology Society

Breaking Down the Rationale for Targeting TROP2 in TNBC

Expert Guidance on Frequently Asked Questions Regarding the Use of ADCs in TNBC

Establishing the Rationale for ADC and ICI Combinations in TNBC

Dissecting Clinical Trial and Real-World Data for ADCs in TNBC

Evaluating the Latest Data and Ongoing Trials for Novel ADC Approaches in TNBC

Breaking Down the Latest Clinical Data for First-line Maintenance and R/R SCLC

Optimizing Treatment for Biliary Tract Cancers

Cross-Disease Integration of Immunotherapy Innovations

Broadening the Frontline—Studies Informing the Use of Immunotherapy in Hepatocellular Carcinoma

Expert Roundtable and Panel Discussions: Current and Future Landscape of TNBC

PER Resource Center: Integrating Novel Approaches in TNBC – New Avenues for TROP2-Targeting ADCs and Beyond – Nursing

Practical Considerations and Future Directions for New Treatment Strategies in SCLC

Show Me the Data®: New and Emerging Roles for Oral SERD Therapy in the Treatment of ER+/HER2– Breast Cancer

Navigating Treatment Gaps in SCLC: Relapse, Resistance, and Need for New Options

Medical Crossfire® in Adjunctive Testing: Charting a New Course in Prostate Cancer Risk Assessment

Imaging Matters: Decoding PSMA PET for Better Decision-Making

Ready for Radioligand Therapy? Patient Selection and Sequencing Simplified

BURST CME™ Resource Center: Integrating Novel PSMA-Directed Radioligand Approaches for Diagnosis and Management of Prostate Cancer

Working Together: Overcoming Barriers to Optimize Outcomes in Patients Treated With Radioligand Therapy Through Multidisciplinary Care

Radioligand Therapy 101: The Science Behind the Strategy

Advances in Managing EGFR-Mutant NSCLC: Applying Evidence Across the Disease Continuum

A New Era of Targeted Therapy for Advanced NSCLC: Exploring Future Directions for Bispecific Antibodies and ADCs

Community Practice Connections™: Enhancing Melanoma Outcomes With Intratumoral Oncolytic Immunotherapy–Strategies for the Multidisciplinary Team

Navigating Advances in Neovascular Retinal Disease: Translating Evidence to Practice in AMD, DME, and RVO

Enhancing Prostate Cancer Outcomes – The Role of PSMA and Targeted Treatment Strategies

(CME Track) Antibody–Drug Conjugates in Oncology: The Essentials of AE Management for Better Patient Outcomes

Community Practice Connections™: Optimizing SCLC Treatment Strategies and Managing Adverse Events Across Disease Stages

Personalized Approaches in NSCLC: Early Detection, Molecular Testing, and Targeted Therapies

9th Annual School of Nursing Oncology™

Community Practice Connections™: DLL3-Targeting Bispecific Antibodies for Small Cell Lung Cancer—From Innovation to Practice

Trending on OncLive

Vopimetostat Plus Daraxonrasib Yields 92% ORR in MTAP-Deleted, RAS-Mutant Pancreatic Cancer

KEYNOTE-D46 Trial Is Discontinued With Sacituzumab Govitecan Plus Pembrolizumab in PD-L1–High NSCLC

GU Cancer Experts Highlight the Most Impactful and Discussion-Worthy Data Presented at ASCO 2026

Subcutaneous Isatuximab Administered Via OBI Approved in EU for Multiple Myeloma

May’s GI Monthly Rewind: A Landmark Approval in CCA, Expanded Access for Daraxonrasib, and More Key Pipeline Updates